Glossary of Terms Related to Patient and Medication Safety
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Artificial Intelligence in Health Care: the Hope, the Hype, the Promise, the Peril
Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril Michael Matheny, Sonoo Thadaney Israni, Mahnoor Ahmed, and Danielle Whicher, Editors WASHINGTON, DC NAM.EDU PREPUBLICATION COPY - Uncorrected Proofs NATIONAL ACADEMY OF MEDICINE • 500 Fifth Street, NW • WASHINGTON, DC 20001 NOTICE: This publication has undergone peer review according to procedures established by the National Academy of Medicine (NAM). Publication by the NAM worthy of public attention, but does not constitute endorsement of conclusions and recommendationssignifies that it is the by productthe NAM. of The a carefully views presented considered in processthis publication and is a contributionare those of individual contributors and do not represent formal consensus positions of the authors’ organizations; the NAM; or the National Academies of Sciences, Engineering, and Medicine. Library of Congress Cataloging-in-Publication Data to Come Copyright 2019 by the National Academy of Sciences. All rights reserved. Printed in the United States of America. Suggested citation: Matheny, M., S. Thadaney Israni, M. Ahmed, and D. Whicher, Editors. 2019. Artificial Intelligence in Health Care: The Hope, the Hype, the Promise, the Peril. NAM Special Publication. Washington, DC: National Academy of Medicine. PREPUBLICATION COPY - Uncorrected Proofs “Knowing is not enough; we must apply. Willing is not enough; we must do.” --GOETHE PREPUBLICATION COPY - Uncorrected Proofs ABOUT THE NATIONAL ACADEMY OF MEDICINE The National Academy of Medicine is one of three Academies constituting the Nation- al Academies of Sciences, Engineering, and Medicine (the National Academies). The Na- tional Academies provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. -
Communicable Disease Chart
COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious; -
The Evolutionary History of the Human Face
This is a repository copy of The evolutionary history of the human face. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/145560/ Version: Accepted Version Article: Lacruz, Rodrigo S, Stringer, Chris B, Kimbel, William H et al. (5 more authors) (2019) The evolutionary history of the human face. Nature Ecology and Evolution. pp. 726-736. ISSN 2397-334X https://doi.org/10.1038/s41559-019-0865-7 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ THE EVOLUTIONARY HISTORY OF THE HUMAN FACE Rodrigo S. Lacruz1*, Chris B. Stringer2, William H. Kimbel3, Bernard Wood4, Katerina Harvati5, Paul O’Higgins6, Timothy G. Bromage7, Juan-Luis Arsuaga8 1* Department of Basic Science and Craniofacial Biology, New York University College of Dentistry; and NYCEP, New York, USA. 2 Department of Earth Sciences, Natural History Museum, London, UK 3 Institute of Human Origins and School of Human Evolution and Social Change, Arizona State University, Tempe, AZ. -
Internal Medicine Milestones
Internal Medicine Milestones The Accreditation Council for Graduate Medical Education Implementation Date: July 1, 2021 Second Revision: November 2020 First Revision: July 2013 ©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Internal Medicine Milestones on a non-exclusive basis for educational purposes. Internal Medicine Milestones The Milestones are designed only for use in evaluation of residents in the context of their participation in ACGME-accredited residency programs. The Milestones provide a framework for the assessment of the development of the resident in key dimensions of the elements of physician competency in a specialty or subspecialty. They neither represent the entirety of the dimensions of the six domains of physician competency, nor are they designed to be relevant in any other context. ©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Internal Medicine Milestones on a non-exclusive basis for educational purposes. i Internal Medicine Milestones Work Group Eva Aagaard, MD, FACP Jonathan Lim, MD Cinnamon Bradley, MD Monica Lypson, MD, MHPE Fred Buckhold, MD Allan Markus, MD, MS, MBA, FACP Alfred Burger, MD, MS, FACP, SFHM Bernadette Miller, MD Stephanie Call, MD, MSPH Attila Nemeth, MD Shobhina Chheda, MD, MPH Jacob Perrin, MD Davoren Chick, MD, FACP Raul Ramirez Velazquez, DO Jack DePriest, MD, MACM Rachel Robbins, MD Benjamin Doolittle, MD, MDiv Jacqueline Stocking, PhD, MBA, RN Laura Edgar, EdD, CAE Jane Trinh, MD Christin Giordano McAuliffe, MD Mark Tschanz, DO, MACM Neil Kothari, MD Asher Tulsky, MD Heather Laird-Fick, MD, MPH, FACP Eric Warm, MD Advisory Group Mobola Campbell-Yesufu, MD, MPH Subha Ramani, MBBS, MMed, MPH Gretchen Diemer, MD Brijen Shah, MD Jodi Friedman, MD C. -
Racial and Ethnic Disparities in Health Care, Updated 2010
RACIAL AND ETHNIC DISPARITIES IN HEALTH CARE, UPDATED 2010 American College of Physicians A Position Paper 2010 Racial and Ethnic Disparities in Health Care A Summary of a Position Paper Approved by the ACP Board of Regents, April 2010 What Are the Sources of Racial and Ethnic Disparities in Health Care? The Institute of Medicine defines disparities as “racial or ethnic differences in the quality of health care that are not due to access-related factors or clinical needs, preferences, and appropriateness of intervention.” Racial and ethnic minorities tend to receive poorer quality care compared with nonminorities, even when access-related factors, such as insurance status and income, are controlled. The sources of racial and ethnic health care disparities include differences in geography, lack of access to adequate health coverage, communication difficulties between patient and provider, cultural barriers, provider stereotyping, and lack of access to providers. In addition, disparities in the health care system contribute to the overall disparities in health status that affect racial and ethnic minorities. Why is it Important to Correct These Disparities? The problem of racial and ethnic health care disparities is highlighted in various statistics: • Minorities have less access to health care than whites. The level of uninsurance for Hispanics is 34% compared with 13% among whites. • Native Americans and Native Alaskans more often lack prenatal care in the first trimester. • Nationally, minority women are more likely to avoid a doctor’s visit due to cost. • Racial and ethnic minority Medicare beneficiaries diagnosed with dementia are 30% less likely than whites to use antidementia medications. -
Series 1100TDM Tandem MEGALUG Mechanical Joint Restraint
Series 1100TDM Tandem MEGALUG® Mechanical Joint Restraint High Pressure Restraint for Ductile Iron Pipe Features and Applications: • For use on Ductile Iron Pipe 4 inch through 54 inch • High Pressure Restraint • Torque Limiting Twist-Off Nuts • Mechanical Joint follower gland incorporated into the restraint • MEGA-BOND® Coating System For more information on MEGA- BOND, visit our web site at www. ebaa.com • Minimum 2 to 1 Safety Factor Series 1112TDM restraining a mechanical joint fitting. • Constructed of A536 Ductile Iron Post Pressure Rating • EBAA-Seal™ Mechanical Nominal Pipe Shipping Assembly (PSI) Joint Gaskets are provided Size Weights* Deflection with all 1100TDM MEGALUG 4 21.6 3° 700 restraints. These are required 6 33.0 3° 700 to accommodate the pressure ratings and safety factors 8 40.0 3° 700 shown. 10 60.2 3° 700 12 75.0 3° 700 • New: High strength heavy hex 14 112.7 2° 700 machine bolts with T-nuts are 16 131.6 2° 700 provided to facilitate easier assembly due to the fittings 18 145.2 1½° 500 radius area prohibiting the use 20 166.6 1½° 500 longer T-bolts. 24 290.2 1½° 500 30 457.9 1° 500 • T-Nuts constructed of High 36 553.63 1° 500 Tensile Ductile Iron with Fluropolymer Coating. 42 1,074.8 1° 500 48 1,283.1 1° 500 For use on water or wastewater 54 1,445.32 ½° 400 pipelines subject to hydrostatic NOTE: For applications or pressures other than those shown please pressure and tested in accordance contact EBAA for assistance. -
Effects of Glans Penis Augmentation Using Hyaluronic Acid Gel for Premature Ejaculation
International Journal of Impotence Research (2004) 16, 547–551 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation JJ Kim1, TI Kwak1, BG Jeon1, J Cheon1 and DG Moon1* 1Department of Urology, Korea University College of Medicine, Sungbuk-ku, Seoul, Korea The main limitation of medical treatment for premature ejaculation is recurrence after withdrawal of medication. We evaluated the effect of glans penis augmentation using injectable hyaluronic acid (HA) gel for the treatment of premature ejaculation via blocking accessibility of tactile stimuli to nerve receptors. In 139 patients of premature ejaculation, dorsal neurectomy (Group I, n ¼ 25), dorsal neurectomy with glandular augmentation (Group II, n ¼ 49) and glandular augmentation (Group III, n ¼ 65) were carried out, respectively. Two branches of dorsal nerve preserving that of midline were cut at 2 cm proximal to coronal sulcus. For glandular augmentation, 2 cc of HA was injected into the glans penis, subcutaneously. At 6 months after each procedure, changes of glandular circumference were measured by tapeline in Groups II and III. In each groups, ejaculation time, patient’s satisfaction and partner’s satisfaction were also assessed. There was no significant difference in preoperative ejaculation time among three groups. Preoperative ejaculation times were 89.2740.29, 101.54759.42 and 96.5752.32 s in Groups I, II and III, respectively. Postoperative ejaculation times were significantly increased to 235.6758.6, 324.247107.58 and 281.9793.2 s in Groups I, II and III, respectively (Po0.01). -
Sports Medicine Examination Outline
Sports Medicine Examination Content I. ROLE OF THE TEAM PHYSICIAN 1% A. Ethics B. Medical-Legal 1. Physician responsibility 2. Physician liability 3. Preparticipation clearance 4. Return to play 5. Waiver of liability C. Administrative Responsibilities II. BASIC SCIENCE OF SPORTS 16% A. Exercise Physiology 1. Training Response/Physical Conditioning a.Aerobic b. Anaerobic c. Resistance d. Flexibility 2. Environmental a. Heat b.Cold c. Altitude d.Recreational diving (scuba) 3. Muscle a. Contraction b. Lactate kinetics c. Delayed onset muscle soreness d. Fiber types 4. Neuroendocrine 5. Respiratory 6. Circulatory 7. Special populations a. Children b. Elderly c. Athletes with chronic disease d. Disabled athletes B. Anatomy 1. Head/Neck a.Bone b. Soft tissue c. Innervation d. Vascular 2. Chest/Abdomen a.Bone b. Soft tissue c. Innervation d. Vascular 3. Back a.Bone b. Soft tissue c. Innervation 1 d. Vascular 4. Shoulder/Upper arm a. Bone b. Soft tissue c. Innervation d. Vascular 5. Elbow/Forearm a. Bone b. Soft tissue c. Innervation d. Vascular 6. Hand/Wrist a. Bone b. Soft tissue c. Innervation d. Vascular 7. Hip/Pelvis/Thigh a. Bone b. Soft tissue c. Innervation d. Vascular 8. Knee a. Bone b. Soft tissue c. Innervation d. Vascular 9. Lower Leg/Foot/Ankle a. Bone b. Soft tissue c. Innervation d. Vascular 10. Immature Skeleton a. Physes b. Apophyses C. Biomechanics 1. Throwing/Overhead activities 2. Swimming 3. Gait/Running 4. Cycling 5. Jumping activities 6. Joint kinematics D. Pharmacology 1. Therapeutic Drugs a. Analgesics b. Antibiotics c. Antidiabetic agents d. Antihypertensives e. -
Different Perspectives for Assigning Weights to Determinants of Health
COUNTY HEALTH RANKINGS WORKING PAPER DIFFERENT PERSPECTIVES FOR ASSIGNING WEIGHTS TO DETERMINANTS OF HEALTH Bridget C. Booske Jessica K. Athens David A. Kindig Hyojun Park Patrick L. Remington FEBRUARY 2010 Table of Contents Summary .............................................................................................................................................................. 1 Historical Perspective ........................................................................................................................................ 2 Review of the Literature ................................................................................................................................... 4 Weighting Schemes Used by Other Rankings ............................................................................................... 5 Analytic Approach ............................................................................................................................................. 6 Pragmatic Approach .......................................................................................................................................... 8 References ........................................................................................................................................................... 9 Appendix 1: Weighting in Other Rankings .................................................................................................. 11 Appendix 2: Analysis of 2010 County Health Rankings Dataset ............................................................ -
The Financial and Human Cost of Medical Error
The Financial and Human Cost of Medical Error ... and How Massachusetts Can Lead the Way on Patient Safety JUNE 2019 EXECUTIVE DIRECTOR Barbara Fain BOARD MEMBERS Maura Healey Attorney General Marylou Sudders Secretary of Health and Human Services Edward Palleschi Undersecretary of Consumer Affairs and Business Regulation Ray Campbell Executive Director of the Center for Health Information and Analysis PREFACE AND ACKNOWLEDGEMENTS This report, and the two research studies upon which it is based, aims to fill information gaps about the incidence and key risks to patient safety in Massachusetts, increase our understanding of how medical error impacts Massachusetts patients and families and, most importantly, propose a new, concerted effort to reduce medical error in all health care settings in the Commonwealth. Many individuals and organizations made meaningful contributions to this work, for which we are extremely grateful: • Betsy Lehman Center Research Advisory Committee, whose members • SSRS, which fielded the survey, including David Dutwin, PhD; Susan offered insightful feedback on our methodologies and analyses including: Sherr, PhD; Erin Czyzewicz, MEd, MS; and A.J. Jennings David Auerbach, PhD, Health Policy Commission; Laura Burke, MD, • Center for Health Information and Analysis (CHIA), especially Ray Harvard Global Health Institute; Ray Campbell, JD, MPA, Center for Campbell, JD, MPA; Lori Cavanaugh, MPH; Amina Khan, PhD; Mark Health Information and Analysis; Katherine Fillo, PhD, RN, Massachusetts Paskowsky, MPP; Deb Schiel, -
Chapter 14. Anthropometry and Biomechanics
Table of contents 14 Anthropometry and biomechanics........................................................................................ 14-1 14.1 General application of anthropometric and biomechanic data .....................................14-2 14.1.1 User population......................................................................................................14-2 14.1.2 Using design limits ................................................................................................14-4 14.1.3 Avoiding pitfalls in applying anthropometric data ................................................14-6 14.1.4 Solving a complex sequence of design problems ..................................................14-7 14.1.5 Use of distribution and correlation data...............................................................14-11 14.2 Anthropometric variability factors..............................................................................14-13 14.3 Anthropometric and biomechanics data......................................................................14-13 14.3.1 Data usage............................................................................................................14-13 14.3.2 Static body characteristics....................................................................................14-14 14.3.3 Dynamic (mobile) body characteristics ...............................................................14-28 14.3.3.1 Range of whole body motion........................................................................14-28 -
797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer
Medical Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History • Endnotes Policy Number: 797 BCBSA Reference Number: 2.04.141 Related Policies Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer, #336 Policy1 Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Plasma-based comprehensive somatic genomic profiling testing (CGP) using Guardant360® for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is considered MEDICALLY NECESSARY when the following criteria have been met: Diagnosis: • When tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), AND • When prior results for ALL of the following tests are not available: o EGFR single nucleotide variants (SNVs) and insertions and deletions (indels) o ALK and ROS1 rearrangements o PDL1 expression. Progression: • Patients progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels, and ALK and ROS1 rearrangements, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP), OR • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs). If no genetic alteration is detected by Guardant360®, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered. Other plasma-based CGP tests are considered INVESTIGATIONAL. CGP and the use of circulating tumor DNA is considered INVESTIGATIONAL for all other indications. 1 The use of circulating tumor cells is considered INVESTIGATIONAL for all indications.